Doctor of Osteopathy Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Van Nguyen

Pain Medicine Lancaster, PA Doctor of Osteopathy

NPI 1700311404 CMS profile 11625501

170 N Pointe Blvd, Lancaster, PA 17601

Open in the dashboard

General payments

$4,026

66 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Van Nguyen of Lancaster, PA is reported in the CMS Open Payments database as having received $4,026 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,808 59
2024 General $1,219 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Van Nguyen
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Van Nguyen were reported at $2,808. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Van Nguyen Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $0 $335 $103–$1,149 $149
2023 $0 $376 $114–$1,228 $160
2024 $1,219 $387 $115–$1,173 $164
2025 $2,808 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Pacira Pharmaceuticals Incorporated $1,019 4 payments
  2. Boston Scientific Corporation $717 14 payments
  3. Abbott Laboratories $598 11 payments
  4. Medtronic, Inc. $584 8 payments
  5. Nalu Medical, Inc. $425 8 payments
  6. Globus Medical, Inc. $250 5 payments
  7. Stryker Corporation $217 6 payments
  8. BIOTRONIK NRO, Inc. $171 8 payments
  9. Novus Surgical Consultants $47 2 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $2,836 58 payments
  2. Travel and Lodging $1,190 8 payments
Products named General payments · program years 2024–2025
  1. Iovera $1,019 4 payments
  2. Intracept $440 11 payments
  3. Nalu Neurostimulation System $425 8 payments
  4. INTELLIS ADAPTIVESTIM $326 5 payments
  5. Senza $232 4 payments
  6. ETERNA $209 2 payments
  7. INCEPTIV $202 2 payments
  8. General - Pain Management $177 2 payments
  9. Prospera $171 8 payments
  10. MILD DEVICE KIT $170 3 payments
  11. Other $610 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

633

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$7,987

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

2.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 182 $2,511
Pregabalin Generic 62 $1,757
Oxycodone Hcl Generic 48 $758
Duloxetine Hcl Generic 25 $439
Tizanidine Hcl Generic 71 $410
Methocarbamol Generic 27 $382
Morphine Sulfate Er Morphine Sulfate Brand 14 $375
Cyclobenzaprine Hcl Generic 42 $327
Baclofen Generic 24 $274
Amitriptyline Hcl Generic 31 $271

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$13,698

Medicare's payments for the services billed

Medicare patients

76

Average age 75

Services billed

356

45 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Diabetes 25%
Depression 25%
Ischemic heart disease 22%
Chronic kidney disease 22%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record